CRISPR-Cas9 protein (NLS)
-
- Antigène
- CRISPR-Cas9
- Type de proteíne
- Recombinant
-
Origine
- Streptococcus pyogenes
-
Source
- Escherichia coli (E. coli)
- Purification/Conjugué
- NLS
- Application
- Genome Editing with Engineered Nucleases (GEEN)
- Fonction
- Ultra NLS-Cas9-basic
- Attributs du produit
- Recombinant Streptococcus pyogenes Cas9 gene expressed in an Escherichia coli with a N-terminal nucleic localization signal (NLS).
- Purification
- Escherichia coli expression system
- niveau d'endotoxine
- 10 EU/mg as analyzed by gel clotting method
-
-
- Indications d'application
-
CRISPR Genomic editing
The optimal working dilution should be determined by the end user. - Procédure de l'essai
-
Cleavage assay: A 20 uL reaction in 1xCas9 Nuclease Reaction Buffer containing 160 ng linearized plasmid, 100 ng gRNA, and 50 ng Ultra NLS-Cas9-basic for 2 hours at 37°C results in a digestion efficiency of linearized plasmid higher than 90%, as determined by agarose gel electrophoresis.
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Buffer
- In 25 mM Tris, 300 mM NaCl, 0.1 mM EDTA, pH 8.0 (50 % glycerol).
- Agent conservateur
- Other preservative
- Stock
- -20 °C
-
- Antigène
- CRISPR-Cas9
- Autre désignation
- Cas9 nuclease
-